Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice
Section snippets
Methods
The RIVA-PCI (rivaroxaban in patients with AF undergoing PCI) registry is a prospective, noninterventional, multicenter observational study on consecutive patients with nonvalvular AF who underwent PCI during hospital stay.12 RIVA-PCI was an observational study and patient participation had no impact on his or her indication for treatment, diagnostics, or therapy. Inclusion in the registry was completely independent of the medical treatment. The RIVA-PCI registry has been registered under
Results
Between January 2018 and March 2020, a total of 1,636 patients were enrolled at 51 German hospitals.12 Of these, 700 patients were treated with rivaroxaban. The baseline characteristics and procedural features of patients treated with and without rivaroxaban are shown in Table 1. Important differences in baseline characteristics between patients enrolled in the PIONEER-AF PCI trial and the RIVA-PCI registry are shown in Table 2. Doses of rivaroxaban were 15 mg in 86.0%, 20 mg in 5.2%, and 10 mg
Discussion
To the best of our knowledge, this is the first prospective real-world registry evaluating the persistence to rivaroxaban, and the efficacy and safety of rivaroxaban after PCI in patients with AF. The number of patients with rivaroxaban enrolled in RIVA-PCI (n = 700) is comparable to the number of patients treated with 15 or 10 mg rivaroxaban in the randomized PIONEER-AF PCI trial (n = 694).7 Follow-up duration was 14 months in RIVA-PCI compared with 12 months in PIONEER-AF PCI.
At baseline,
Disclosures
Dr. Zeymer: speakers honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim; Daichi Sankyo, Pfizer, Sanofi; Dr. Hennersdorf: speakers honoraria from AstraZeneca, Bayer, Berlin Chemie, Daiichi Sankyo. The remaining authors have no conflicts of interest to declare.
Acknowledgment
List of investigators (in the order of the number of enrolled patients):
Ralph Toelg MD, Segeberger Kliniken GmbH, Bad Segeberg; Prof. Harm Wienbergen MD, Klinikum Links der Weser Bremen, Bremen; Prof. Uwe Zeymer MD, Klinikum der Stadt Ludwigshafen, Ludwigshafen; Hans-Peter Hobbach, Kreisklinikum Siegen, Siegen; Alessandro Cuneo MD, Krankenhaus und MVZ Maria-Hilf Stadtlohn, Stadtlohn; Prof. Raffi Bekeredjian MD, Robert-Bosch-Klinikum, Stuttgar; Prof. Oliver Ritter MD, Klinikum Brandenburg Havel,
References (24)
- et al.
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
Lancet
(2013) - et al.
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Lancet
(2019) - et al.
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
J Thromb Haemost
(2005) - et al.
Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation
J Am Coll Cardiol
(2017) - et al.
Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry
Eur Heart J Acute Cardiovasc Care
(2019) - et al.
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Clin Res Cardiol
(2018) - et al.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Eur Heart J
(2016) - et al.
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
N Engl J Med
(1996) - et al.
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endor sed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)
Eur Heart J
(2014) - et al.
Prevention of bleeding in patients with atrial fibrillation undergoing PCI
N Engl J Med
(2016)
RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
N Engl J Med
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
N Engl J Med
Cited by (1)
Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation
2023, Expert Review of Cardiovascular Therapy
Funding: This study was supported by an unrestricted grant of Bayer, Germany.